Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc has demonstrated a positive financial trajectory, reporting an 18% year-over-year revenue increase to $483 million, with a robust peak sales guidance that forecasts over $1 billion by 2029. The company's strategic initiatives, such as the ongoing Phase 3 trial for IBSRELA and enhanced prescription metrics for XPHOZAH, including a notable 41% growth in its ex-Medicare segment, indicate strong market demand and potential for substantial future growth. Ardelyx's investments in patient assistance programs and sales infrastructure are expected to further boost prescription volumes and overall revenue performance.

Bears say

Ardelyx Inc. faces a challenging outlook as management anticipates a typical seasonal decline in Ibsrela revenue, projecting an 18% quarter-over-quarter drop for 1Q26 despite an overall estimate of $422M for FY26. The company's aggressive guidance of over $1B in peak Ibsrela net sales appears unrealistic, compounded by potential adverse effects from changing reimbursement pricing structures and the risk of key product labels lacking essential features. Additionally, Ardelyx reported a net loss of $0.4M for 4Q25, highlighting concerns over market penetration and revenue generation, particularly as adherence issues with phosphate binder therapy persist, affecting patient treatment outcomes.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.